PROSCA/BLADDR 2022 | New concepts in prostate cancer pathology

Eva Compérat, MD, PhD, Hôpital Tenon, Sorbonne University, Paris, France, discusses new concepts in prostate cancer pathology as discussed during the Prostate and Bladder Cancer (PROSCA/BLADDR) annual meeting, highlighting intraductal carcinoma and cribriform tumors as predictive factors for poor outcomes, and therefore these patients should not be directed to active surveillance. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.